Next Phase Newsletter

A newly established venture capital firm is dedicated to funding private, early stage, pre-clinical and clinical neuroscience therapeutics and technologies for neurological and psychiatric diseases and disorders. The firm invests in Seed and Series A rounds, typically allocating $1-10 million USD for each deal. The firm looks for deals globally and plans to make 8-10 investments in the upcoming year. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on treating those with psychiatric and neurological diseases. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered. The firm is primarily interested in therapeutics and technologies that are pre-clinical or in development.

The firm sometimes prefers to take a board seat in companies in which they invest and prefers management teams that have a strong technical background within the clinical neuroscience area of focus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global medical corporation headquartered in the USA is interested in making acquisitions and distribution agreements in the medical device sector, and does not invest in equity financing rounds. The firm typically makes 6-12 deals per year, including both early stage and mature companies. The firm will consider medical device opportunities worldwide.

The firm is interested in novel medical devices that fit into their existing clinical areas: anesthesia, respiratory devices, venous access, interventional devices (primarily in cardiology), surgical devices (with a focus on minimally invasive access and closure), urology, and OEM. In general, the firm prefers that products already have regulatory approval, but this is not an absolute requirement. The firm mostly focuses on devices that use a 510k pathway.

The firm focuses on products that have strong IP portfolios, good gross margins (65% or over) and which have the potential to really occupy an important market position. The firm has a global presence and therefore focuses on acquisitions and global rights rather than regional distribution.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital company founded in 2005 manages just under $50 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Healthcare IT products, Life Science Research Tools and Medical Devices with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Germany and Switzerland specializes in early-stage and growth capital investments in the Technology and Life Sciences sectors. The firm has approximately €1Bn AUM and is currently investing out of a €150M fund dedicated to the Life Sciences. Depending on the stage of the company, the firm can allocate up to €15M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndication. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

In the life sciences sector, the firm invests in therapeutics, medical technology, diagnostics, and digital medicine, and is opportunistic in terms of subsectors and indications. In therapeutics, the firm mainly focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms. In diagnostics and medtech, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product. In digital medicine, the firm looks for data-driven technologies being applied clinically to drive meaningful change in patient outcomes.

The firm typically requests a board seat and looks for a strong and experienced management team, but will also support highly talented fledgling entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science investment arm of a global private equity firm with $24 billion in assets under management may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide. In addition to making equity investments from the life science investment arm, the firm also has another fund that invests in early growth companies in the medical device, healthcare IT and diagnostics sectors.

The life science investment arm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the arm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the arm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The arm will consider investments in any indication or technology area.

The growth investment arm invests in digital health, medtech and diagnostics companies with revenue streams, and uses a variety of structures to provide credit or royalty financing to early growth stage companies.

The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, the firm is open to working to fill or change the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based foundation that was established in 1998 is currently funding new investment opportunities in the life science space (specifically Alzheimer’s disease and related dementia) through two grants; the first program is for existing early stage private companies, and the second program supports the establishment of new companies. The foundation typically provides funding of up to $350,000 per year for up to two years for pre-clinical programs or $1-3 M for clinical stage programs. The foundation will invest with other groups for larger deals. The foundation typically provides investments as equity, a convertible loan, and recoverable grants, and will consider investments globally.

The foundation is currently most interested in companies in the therapeutics space but will consider diagnostics, if the technology provides significant benefit for Alzheimer’s patients or will accelerate clinical trials. The firm is interested in both small molecules and biologics and will providing funding from companies anywhere from high throughput screening to Phase IIa of Clinical Trials.

The foundation is looking for companies with experienced management teams. The foundation looks to be an active value-added investor to help companies with securing future financing rounds when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A micro VC fund was founded in 2017 in the USA by a group of alumni from an established China-based university. The group has raised three funds in the past and is currently investing from the firm’s first fund of of $50 million since early 2017. The group focuses on Angel to Series A stage companies across various sectors, including pharmaceutical, medical device and healthcare IT. The typical investment size is no more than $500,000, but the group will syndicate with other investors for larger investments. The firm looks to make investments in US companies with markets in US and/or China.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed round and series A round. Historically, the fund has been active in life science companies developing synthetic organelles-based research tools, nanoparticle research reagents and devices, web-based EMR system, proprietary screening and diagnostic tests for cancer, drug authentication platform and patient recovery technologies.

The firm focuses on investments in private companies and typically invests in pre-revenue companies with strong and experienced management team. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.